DK2938598T3 - Substitueret phthalazin-1(2H)-on-derivater som selektive hæmmere af poly-(adp-ribose-)polymerase-1 - Google Patents

Substitueret phthalazin-1(2H)-on-derivater som selektive hæmmere af poly-(adp-ribose-)polymerase-1 Download PDF

Info

Publication number
DK2938598T3
DK2938598T3 DK13828996.2T DK13828996T DK2938598T3 DK 2938598 T3 DK2938598 T3 DK 2938598T3 DK 13828996 T DK13828996 T DK 13828996T DK 2938598 T3 DK2938598 T3 DK 2938598T3
Authority
DK
Denmark
Prior art keywords
groups
alkyl
cycloalkyl
heterocyclyl
nr6r7
Prior art date
Application number
DK13828996.2T
Other languages
English (en)
Inventor
Brijesh K Srivastava
Ranjit C Desai
Pankaj R Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54198806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2938598(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Application granted granted Critical
Publication of DK2938598T3 publication Critical patent/DK2938598T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Claims (10)

1. Forbindelse med strukturen i den almene formel (I)
(i) hvor R1 ved hver forekomst uafhængigt er udvalgt blandt H, halogen, eller grupperne udvalgt blandt (CrCi2)alkyl, haloalkyl, cycloalkyl, alkylthio eller (OS02)alkyl-gruppen, hvor hver af disse grupper er yderligere substitueret med egnede substituenter udvalgt blandt hydroxyl-, oxo-, halo-, thio-, nitro-, amino-, alkyl-, alkoxy-, haloalkyl- og haloalkoxygrupper; R' ved hver forekomst uafhængigt er udvalgt blandt halogen-, alkyl-, alkoxy-, hydroxyl-, haloalkyl-, haloalkoxy-, cyano-, thioalkyl-, cycloalkylgrupper; m = 1-4; L= -O, -S, -NH; n = 0-4; R2 er udvalgt blandt substituentgrupper bestående af hydrogenatom, hydroxyl, alkyl, cycloalkyl, oxo, C(0)0R5, -C(0)R5 eller -C(0)NR6R7, hvor alkyl- og cycloalkylgrupperne yderligere er substitueret med en eller flere substituenter udvalgt blandt halogen-, hydroxyl-, alkyl- eller alkoxygrupper; R3 og R4 hver især uafhængigt er udvalgt blandt hydrogenatom, alkyl, hydroxyl, alkoxy, cycloalkyl, -C(0)0R5, -0C(0)R5, -0(CH2)pC(0)0R5, -C(0)R5, -NHC(0)R5, -NR6R7, -0C(0)NR6R7 eller -C(0)NR6R7 eller alternativt, R3 og R4 tilsammen danner en oxogruppe; hver af ringatomerne 'D' og Έ' uafhængigt er udvalgt blandt C- eller N-atomer; Ό' og Έ' er forbundet med hinanden for at danne en 5-leddet ring 'X', hvor 'X' er udvalgt blandt heterocyclyl og heteroaryl, hvor heterocyclyl og heteroaryl er substitueret med en eller flere egnede substituenter udvalgt blandt hydrogen-, cyano-, halogen-, hydroxyl-, oxo-, eventuelt substituerede grupper udvalgt blandt alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, benzyl, OR5, -C(0)0R5, -0C(0)R5, -0(CH2)pC(0)0R5, C(0)R5, S(0)qR5, -NHC(0)R5 NR6R7, -0C(0)NR6R7 eller -C(0)NR6R7, og hvor alkyl-, cycloalkyl-, heterocy-clyl-, aryl-, heteroaryl- eller benzylgruppen hver især uafhængigt kan være yderligere substitueret med en eller flere substituenter udvalgt blandt alkyl-, halogen-, hydroxyl-, alkoxy-, cycloalkyl-, heterocyclyl-, aryl-, heteroaryl-, oxo-, -C(0)0R5-, -0C(0)R5-, 0(CH2)PC(0)0R5-, -C(0)R5-, -S(0)qR5-, -NHC(0)R5-, NR6R7-, -0C(0)NR6R7- eller -C(0)NR6R7-grupper; R5 ved hver forekomst uafhængigt er udvalgt blandt hydrogenatom, eventuelt substituerede grupper udvalgt blandt alkyl-, cycloalkyl-, heterocyclyl-, aryl-eller heteroarylgrupper, hvor de eventuelle substituenter er udvalgt blandt alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylsyre eller carboxylsyreester; hver af R6 eller R7 ved hver forekomst uafhængigt er udvalgt blandt H, eventuelt substituerede grupper udvalgt blandt alkyl, cycloalkyl, heterocyclyl, aryl eller heteroaryl, hvor de eventuelle substituenter uafhængigt er udvalgt blandt alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylsyre eller carboxylsyreester; eller R6 og R7 er forbundet med hinanden sammen med nitrogenatomet for at danne en heterocyclylring; hvor heterocyclyl ri ngen indeholder et eller flere heteroatomer udvalgt blandt N, O, S(0)q, q er 0,1 eller 2 og p er 0,1 eller 2.
2. Forbindelse ifølge krav 1, hvor heterocyklussen, der betegner
er udvalgt blandt de følgende bicykliske ringe nævnt nedenfor
3. Forbindelse ifølge krav 1, hvor substituenterne på ring X er udvalgt blandt halogen, hydroxyl, oxo, eventuelt substituerede grupper udvalgt blandt alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, benzyl, OR5, -C(0)0R5, -0C(0)R5,-0(CH2)pC(0)0R5, C(0)R5, S(0)qR5, -NHC(0)R5, NR6R7, -0C(0)NR6R7 eller -C(0)NR6R7, hvor hver af R5, R6 og R7 er som defineret i krav 1, og hvor alkyl-, cycloalkyl-, heterocyclyl-, aryl-, heteroaryl- eller benzylgruppen hver især uafhængigt yderligere er substitueret med en eller flere substituenter udvalgt blandt alkyl-, halogen-, hydroxyl-, alkoxy-, cycloalkyl-, heterocyclyl-, aryl-, heteroaryl-, oxo-, -C(0)0R5-, -0C(0)R5-, 0(CH2)pC(0)0R5-, -C(0)R5-, -S(0)qR5-, -NHC(0)R5-, NR6R7-, -0C(0)NR6R7-eller -C(0)NR6R7-grupper.
4. Forbindelse ifølge krav 1, hvor "aryl"-grupperne er udvalgt blandt phenyl-, naphthyl-, tetrahydronaphthyl-, indenyl-, dihydroindenyl-, biphenylgrupper; og/eller hvor heteroaryl- eller den heteroaromatiske gruppe er udvalgt blandt pyridyl-, thienyl-, furyl-, pyrrolyl-, indolinyl-, indolyl-, pyridofuranyl-, pyri-dothienyl-, thienopyrimidyl-, quinolinyl-, pyrimidinyl-, pyrazolyl-, quinazolinyl-, pyridazinyl-, purinylgrupper; og/eller hvor heterocyclylgruppen er udvalgt blandt aziridinyl-, azetidinyl-, pyrrolidinyl-, imidazolidinyl-, piperidinyl-, pipera-zinyl-, 2-oxopiperidinyl-, 4-oxopiperidinyl-, 2-oxopiperazinyl-, 3-oxopiperazi-nyl-, morpholinyl-, thiomorpholinyl-, 2-oxomorpholinyl-, azepinyl-, diazepinyl-, oxapinyl-, thiazepinyl-, oxazolidinyl-, thiazolidinyl-, dihydrothiophen-, dihydro-pyran-, dihydrofuran-, dihydrothiazol-, benzopyranyl-, benzopyranonyl-, ben-zodihydrofuranyl-, benzodihydrothienyl-, pyrazolopyrimidonyl-, azaquinazo-linoyl-, thienopyrimidonyl-, quinazolonyl-, pyrimidonyl-, benzoxazinyl-, ben-zoxazinonyl-, benzothiazinyl-, benzothiazinonyl-, thienopiperidinylgrupper.
5. Forbindelse ifølge krav 1, hvor substituenterne på arylgrupper uafhængigt er udvalgt blandt hydrogen-, halogen-, alkyl-, alkoxy-, hydroxyl-, haloalkyl-, haloalkoxy-, cyano-, thioalkyl-, cycloalkylgrupper; og/eller hvor substituenterne på heteroaryl- eller heteroaromatiske grupper er udvalgt blandt hydrogen-, halogen-, alkyl-, alkoxy-, hydroxyl-, haloalkyl-, haloalkoxy-, aryl-, aralkyl-, cy ano-, alkylthio-, thioalkylgrupper; og/eller hvor substituenterne på hete-rocyclylgrupper er udvalgt blandt hydrogen-, halogen-, alkyl-, alkoxy-, hydroxyl-, haloalkyl-, haloalkoxy-, aryl-, aralkyl-, cyano-, alkylthio-, thioalkylgrupper.
6. Forbindelse ifølge krav 1 udvalgt fra gruppen bestående af:
7. Forbindelse ifølge et af de foregående krav udvalgt fra gruppen bestående af:
8. Farmaceutisk sammensætning omfattende en terapeutisk virksom mængde af en forbindelse med Formel (I) ifølge et af de foregående krav og eventuelt en eller flere farmaceutisk acceptable bærere, fortyndingsmidler eller hjælpestoffer.
9. Forbindelse med Formel (I) ifølge et af kravene 1 til 7 til anvendelse ved behandling af cancer.
10. Farmaceutisk sammensætning omfattende en forbindelse med Formel (I) ifølge et af kravene 1 til 7 sammen med en eller flere farmaceutisk acceptable bærere, fortyndingsmidler eller hjælpestoffer til anvendelse ved behandling af cancer.
DK13828996.2T 2012-12-31 2013-12-23 Substitueret phthalazin-1(2H)-on-derivater som selektive hæmmere af poly-(adp-ribose-)polymerase-1 DK2938598T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3742MU2012 2012-12-31
PCT/IN2013/000794 WO2014102817A1 (en) 2012-12-31 2013-12-23 Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1

Publications (1)

Publication Number Publication Date
DK2938598T3 true DK2938598T3 (da) 2017-02-13

Family

ID=54198806

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13828996.2T DK2938598T3 (da) 2012-12-31 2013-12-23 Substitueret phthalazin-1(2H)-on-derivater som selektive hæmmere af poly-(adp-ribose-)polymerase-1

Country Status (30)

Country Link
US (1) US9598418B2 (da)
EP (1) EP2938598B1 (da)
JP (1) JP5930452B2 (da)
KR (1) KR101652654B1 (da)
CN (1) CN104918917A (da)
AP (1) AP2015008439A0 (da)
AR (1) AR094299A1 (da)
AU (1) AU2013368842B2 (da)
BR (1) BR112015012425A2 (da)
CA (1) CA2890309A1 (da)
CL (1) CL2015001655A1 (da)
CO (1) CO7400872A2 (da)
DK (1) DK2938598T3 (da)
EA (1) EA201591239A1 (da)
ES (1) ES2614885T3 (da)
GE (1) GEP201706691B (da)
HK (1) HK1210466A1 (da)
HR (1) HRP20170219T1 (da)
HU (1) HUE030613T2 (da)
IL (1) IL238714A0 (da)
MA (1) MA38080A1 (da)
MX (1) MX2015006780A (da)
NZ (1) NZ708255A (da)
PH (1) PH12015501199A1 (da)
PL (1) PL2938598T3 (da)
PT (1) PT2938598T (da)
SG (1) SG11201503670YA (da)
TW (1) TWI553005B (da)
WO (1) WO2014102817A1 (da)
ZA (1) ZA201503218B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MA38982A1 (fr) 2013-11-26 2017-09-29 Hoffmann La Roche Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
WO2016187620A2 (en) 2015-05-21 2016-11-24 The Regents Of The University Of California Anti-cancer compounds
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
MA42923A (fr) * 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
WO2017050792A1 (en) * 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
WO2017071636A1 (zh) * 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
WO2017101796A1 (zh) * 2015-12-16 2017-06-22 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
IL263917B (en) * 2016-06-24 2022-07-01 Univ California Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN109311897B (zh) 2017-03-20 2021-07-20 福马治疗股份有限公司 作为丙酮酸激酶(pkr)活化剂的吡咯并吡咯组合物
CN109251204A (zh) * 2017-07-13 2019-01-22 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN108164468B (zh) * 2018-02-09 2021-02-02 上海卫岑医药科技有限公司 一种parp抑制剂、其药物组合物、制备方法及应用
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20230159469A1 (en) * 2020-05-08 2023-05-25 Txinno Bioscience Inc. Novel phthalazine derivative having ectonucloeotide pyrophosphatase/phosphodieste rase inhibitory activity, and use thereof
EP4304720A1 (en) * 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
WO2023288002A1 (en) * 2021-07-16 2023-01-19 Oregon Health & Science University Phthalazinone-based parp-1 inhibitors
WO2023174250A1 (en) * 2022-03-15 2023-09-21 Beigene , Ltd. 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5
WO2024046420A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
GB2384776C (en) 2000-10-30 2006-02-03 Kudos Pharm Ltd Phthalazinone derivatives
CA2517629C (en) 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP2305671A1 (en) 2004-01-05 2011-04-06 AstraZeneca AB Thiophene and thiazole derivatives as CHK1 inhibitors
CA2577191A1 (en) 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
WO2006039545A2 (en) 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
EP1869052A1 (en) 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
EP1962843B1 (en) 2005-11-25 2011-02-23 Pharma Mar S.A., Sociedad Unipersonal Use of parp-1 inhibitors
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
MX2009007051A (es) * 2006-12-28 2009-07-10 Abbott Lab Inhibidores de la poli(adp-ribosa) polimerasa.
BRPI0811059A2 (pt) 2007-05-25 2017-05-09 Astrazeneca Ab combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010005070A (es) * 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
HUE030800T2 (en) 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
EP2598491B1 (en) 2010-07-27 2015-09-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
JP5699223B2 (ja) 2010-12-02 2015-04-08 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
RU2606635C2 (ru) 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
CN103242273B (zh) 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
WO2013117288A1 (en) 2012-02-09 2013-08-15 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Also Published As

Publication number Publication date
CA2890309A1 (en) 2014-07-03
CL2015001655A1 (es) 2015-10-02
CO7400872A2 (es) 2015-09-30
AU2013368842B2 (en) 2015-11-12
GEP201706691B (en) 2017-06-26
US20150291603A1 (en) 2015-10-15
AU2013368842A1 (en) 2015-05-21
MA38080A1 (fr) 2018-02-28
AP2015008439A0 (en) 2015-05-31
BR112015012425A2 (pt) 2017-07-11
EA201591239A1 (ru) 2015-10-30
HRP20170219T1 (hr) 2017-04-07
ES2614885T3 (es) 2017-06-02
TWI553005B (zh) 2016-10-11
JP2016504347A (ja) 2016-02-12
SG11201503670YA (en) 2015-07-30
JP5930452B2 (ja) 2016-06-08
PT2938598T (pt) 2017-02-07
PL2938598T3 (pl) 2017-05-31
HUE030613T2 (en) 2017-05-29
US9598418B2 (en) 2017-03-21
KR20150091137A (ko) 2015-08-07
TW201441219A (zh) 2014-11-01
IL238714A0 (en) 2015-07-01
NZ708255A (en) 2016-08-26
EP2938598B1 (en) 2016-12-21
ZA201503218B (en) 2016-01-27
AR094299A1 (es) 2015-07-22
HK1210466A1 (en) 2016-04-22
WO2014102817A1 (en) 2014-07-03
PH12015501199B1 (en) 2015-08-17
MX2015006780A (es) 2015-08-06
KR101652654B1 (ko) 2016-08-30
CN104918917A (zh) 2015-09-16
PH12015501199A1 (en) 2015-08-17
EP2938598A1 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
DK2938598T3 (da) Substitueret phthalazin-1(2H)-on-derivater som selektive hæmmere af poly-(adp-ribose-)polymerase-1
AU2019206013A1 (en) Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
JP2019521992A (ja) Ｆｇｆｒ阻害活性を有する新規な化合物およびその製造と使用
EP2598491B1 (en) Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
AU2016375634B2 (en) Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
WO2012139930A1 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
AU2015281155B9 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on NAE inhibitory effect
KR20080074963A (ko) 단백질 키나제 억제제로서의 이미다조피라진
KR20210153051A (ko) 매크로사이클릭 화합물
JP2015522557A (ja) タンキラーゼのピロロピリミドン及びピロロピリドン阻害剤
TWI773718B (zh) 聚-adp核糖聚合酶（parp）抑制劑
KR20180039669A (ko) 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
CN114437035A (zh) 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
WO2023091726A1 (en) Inhibitors of cyclin‑dependent kinase 12 (cdk12)
OA17331A (en) Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADPribose) polymerase-1.
KR20230171440A (ko) 약학적 화합물
KR20220041121A (ko) 디히드로피리미딘 유도체 및 hbv 감염 또는 hbv-유도성 질환의 치료에 있어서의 이의 용도
Zhao et al. Synthesis and cytotoxicity of novel 3-amido-4-indolylmaleimide derivatives
EA041747B1 (ru) Ингибиторы g12c kras, содержащая их фармацевтическая композиция и использующий их способ лечения рака